Remdesivir - A new open-label trial

We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear*

We review Spinner et al in JAMA 2020, an open label trial of remdesivir 5 days vs remdesivir 10 days vs 'standard of care' for the treatment of #COVID19

Show notes: FOAMcast.org

Thanks for listening,
Lauren Westafer and Jeremy Faust